Laos vs Naoero: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Laos
0.6%
in 2024
Naoero
0.6%
in 2024
Laos rank
60th
Naoero rank
60th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Laos
- Naoero
How they compare
Laos currently reports 0.6% against 0.6% in Naoero, a difference of 0.0%.
The two have swapped places 3 times across 10 shared years of data; in 2015 it was Laos ahead.
Laos ranks 60th and Naoero ranks 60th of 247 countries.
Laos has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Laos | Naoero | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.3% | 1.2% | 0.1% | Laos |
| 2020s | 0.7% | 0.7% | 0.0% | Laos |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Laos or Naoero?
- Laos, at 0.6% against 0.6% in Naoero as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Laos and Naoero?
- 0.0%, with Laos ahead.
- How many years of comparable data are there for Laos and Naoero?
- 10 years are reported by both, from 2015 to 2024.
- How do Laos and Naoero rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Laos ranks 60th and Naoero ranks 60th of 247 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.